Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Ernest Nadal; Delvys Rodríguez‐Abreu; Marta Simó; Bartomeu Massutí; Óscar Juan; G. Huidobro; Rafael López Castro; Javier de Castro; Anna Estival; Joaquín Mosquera; Ivana Sullivan; Enriqueta Felip; Ana Blasco; M. Guirado; Eva Pereira; Noelia Vilariño; Valentín Navarro; Jordi Bruna

doi:10.1200/jco.22.02561

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Atezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nadal et al. (2023) studied this question.

synapsesocial.com/papers/69dc60c8d4d0de07d11332a3 https://doi.org/10.1200/jco.22.02561

View Full Paper

Ask AI

Bookmark

Share

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Ask about this paper

Abstract

Discussion

Cite This Study

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading